Switch to
More onapp

How to use scorecard? Learn more

Mankind Pharma Ltd

MANKIND
Health CarePharmaceuticals
LargecapWith a market cap of ₹86,100 cr, stock is ranked 95
High RiskStock is 3.34x as volatile as Nifty
2,149.3513.75 (+0.64%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
LargecapWith a market cap of ₹86,100 cr, stock is ranked 95
High RiskStock is 3.34x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
49.85
PB RatioPB Ratio
11.29
Dividend YieldDiv. Yield
Sector PESector PE
51.38
Sector PBSector PB
5.89
Sector Div YldSctr Div Yld
0.57%

Forecast & RatingsDetailed Forecast 

55%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Mankind Pharma Limited is an India-based pharmaceutical company. The Company is engaged in developing, manufacturing, and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products. It has a portfolio of formulations in several therapeutic areas, such as anti-infectives, cardiovascular, gastrointestinal, vitamins/minerals/nutrients, respiratory, anti-diabetic, dermatology, gynecology, and pain/analgesics, among others. Its other therapeutic areas include urology, ophthalmology, antiparasitic, stomatological, antineoplastic/immunomodulator, hepatoprotective, anti-malarial, blood-related, hormones, antiviral, sex stimulants/rejuvenators, anti-tuberculosis, parenteral and vaccines. Its portfolio of brands includes Nurokind, Telmikind, Manforce (Rx), Gudcef, Moxikind, Amlokind, Glimestar, Asthakind, Codistar, Candiforce, Mahacef, Dydroboon, Cefakind, Zenflox, Monticope, Dynaglipt, and others.

Investor PresentationView older 

Aug 2, 2023

PDF
View Older Presentations

Financial TrendFinancial statements 

20202021202220235.996.407.998.891.031.271.431.28
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Increased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has increased by 3.66%

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Investor Presentation 
Announced OnJan 31, 2024

Mankind Pharma Limited has informed the Exchange about Investor Presentation | Download

Mankind Pharma Limited has informed the Exchange about Investor Presentation | Download

Press Release 
Announced OnJan 31, 2024

Press Release on Financial Results for the quarter and nine months ended December 31, 2023. | Download

Press Release on Financial Results for the quarter and nine months ended December 31, 2023. | Download

Outcome of Board Meeting 
Announced OnJan 31, 2024

Outcome of Board Meeting held today i.e. January 31, 2024 | Download

Outcome of Board Meeting held today i.e. January 31, 2024 | Download

See all events